GDF11 supplementation improved retinal structure and function in retinal ischemia injury.

Area of Science:

• Ophthalmology
• Neuroscience
• Regenerative Medicine

Background:

• Retinal ischemia is a leading cause of blindness, resulting in neuronal and vascular dysfunction.
• Conditions like diabetic retinopathy and ocular ischemic syndrome are linked to retinal ischemia.
• Growth differentiation factor 11 (GDF11) is known for neuroprotection and promoting angiogenesis in other ischemic conditions.

Purpose of the Study:

• To investigate the protective effects of GDF11 on retinal ischemia.
• To evaluate GDF11's therapeutic potential for preventing vision loss due to retinal ischemia.

Main Methods:

• A mouse model of unilateral common carotid artery occlusion (UCCAO) was used to simulate retinal ischemia.
• Electroretinography (ERG) assessed retinal function, while H&E staining and immunohistochemistry evaluated pathological changes.
• In vivo and in vitro models were used to assess GDF11's impact on angiogenesis.

Main Results:

• GDF11 treatment attenuated acute-phase cell death, edema, gliosis, and apoptosis post-UCCAO.
• In the chronic phase, GDF11 reduced apoptosis and enhanced angiogenesis.
• GDF11's protective effects were mediated by the PI3K/AKT pathway.

Conclusions:

• GDF11 demonstrates significant potential as a novel therapeutic agent for retinal ischemia.
• GDF11 offers therapeutic benefits during both acute and chronic phases of retinal ischemic injury.
• GDF11 may be a valuable treatment for preventing vision loss in various retinal ischemia-related diseases.